Virtual Library
Start Your Search
A. Toker
Author of
-
+
P1.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 224)
- Event: WCLC 2015
- Type: Poster
- Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.08-023 - Induction Chemotherapy Increases the Survival of Patients with Primary Neuroectodermal Tumors of the Thorax (ID 2415)
09:30 - 17:00 | Author(s): A. Toker
- Abstract
Background:
Primary neuroectodermal tumors (PNETs) of the thorax are rare, small-round cell tumors with a poor prognosis despite multimodal therapy, including surgery and chemoradiotherapy. The ideal treatment was unknown since no comparative clinical series with surgical therapy had been reported. We evaluated the results of multimodal treatment in patients with PNETs located in the thoracic region.
Methods:
Between 2000 and 2013, 27 patients with PNETs in the thoracic region were treated in 3 tertiary-care hospitals. There were 15 males and 10 females with a mean age of 26.3 years (range, 6 – 60). The tumor was located in the chest wall in 21 (involving the costovertebral junction in 7), the lung in 6 patients. Thirteen patients had induction chemotherapy, whereas 22 patients underwent resectional surgery. All the patients received adjuvant chemo/radiotherapy.
Results:
There was no hospital mortality. The overall 5-year survival rate was 42% and median survival was 36±14 months in all patients. Five year survival in patients who had induction chemotherapy was 56%, whereas it was 36% in cases who did not receive induction chemotherapy (p=0.045). The 5-year survival rate of patients with and without costovertebral junction involvement was 21% and 64%respectively(p=0.076). The 5-year survival in the patients who had pulmonary involvement without vertebral or chest wall invasion had 50%.
Conclusion:
Primary thoracic PNET is an aggressive entity that often requires multimodal therapy. Induction chemotherapy seems to lead a greater complete resection rate and better survival, while involvement of the costovertebral junction indicates a slightly worse prognosis.
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-049 - Concomitant Chemoradiotherapy with Etoposide & Cisplatin versus Docetaxel & Cisplatin in Locally Advanced Non-Small Cell Lung Cancer (ID 1453)
09:30 - 17:00 | Author(s): A. Toker
- Abstract
Background:
There is currently no consensus regarding which chemotherapy regimen is best to administer with radiotherapy in patients with locally advanced non–small-cell lung cancer. Here, our aim was to compare the outcome of patients treated with either etoposide-cisplatin (EP) or docetaxel-cisplatin (DP) in this curative setting.
Methods:
The patients treated with concurrent radiotherapy with either EP or DP with from 2004 to 2012 were identified. Patients whose medical records and follow up information obtained in details were included to this retrospective study. Survival rates were compared using Cox proportional hazards regression models with adjustments for confounding provided by propensity score methods.
Results:
A total of 105 patients were treated with concurrent chemoradiotherapy for locally advanced (IIB-IIIA-IIIB) non-small cell lung cancer in Istanbul University, Institute of Oncology between 2004 and 2012. Totally 50 patients (median age 54 yr; 32-70 yr) given concurrent EP and 55 patients (median age 55 yr; 37-73) given concurrent DP were enrolled to analyses. There was no statistically significant difference in baseline clinicopathological features including age, gender, performance status, and weight loss, histological subtype, primary lung side, clinical T, N and TNM stages between 2 groups. In univariate analysis, median overall survival of patients treated with EP was found to be higher than that of patients treated with DP (41 months versus 20 months, p= 0.003). Multivariate analysis further revealed survival advantage with EP as compared to DP (hazard ratio [HR], 0.46; 95% CI, 0.25 to 0.83) (p=0.009). Toxicity profile of 2 treatment groups were found to be similar except that pulmonary toxicity was higher in DP group compared to EP (grade 3-4: 0 versus 6%, p= 0.024).
Conclusion:
Concurrent chemoradiotherapy with EP may provide more favorable outcome than that of DP with acceptable safety profile.
